醛固酮合成酶缺陷症患者的追赶生长与氟氢可的松停药
氟氢可的松治疗中位2个月后实现追赶生长,5例在中位6.0岁时可停药;停药后醛固酮合成酶活性仍低于同龄对照,提示需长期监测。
要点
- 氟氢可的松治疗与ASD患儿快速追赶生长及电解质紊乱控制相关。
- 部分患儿随年龄增长可停用氟氢可的松,中位停药年龄6.0岁。
- 停药后醛固酮合成酶活性仍降低,不能达到完全生化缓解,需长期随访。
核心结论
- 氟氢可的松治疗与ASD患儿快速追赶生长和电解质紊乱控制相关。
- 随时间推移盐皮质激素需求下降可用生理适应机制解释,而非醛固酮合成酶活性改善。
- 由于无法实现完全生化缓解,ASD患者需要长期监测。
研究设计与样本
- 多中心研究纳入临床诊断ASD的儿童,记录生长与治疗特征。
- 采用液相色谱-质谱联用测定血浆肾上腺类固醇。
- 通过CYP11B2基因测序和计算机模拟分析确认遗传诊断。
主要发现
- 最常见症状为体重增长不良(56.3%)。
- 氟氢可的松治疗开始中位年龄3.6个月(范围0.9至8.3)。
- 治疗后中位2个月(范围0.5至14.5)实现追赶生长。
- 5例患者在中位年龄6.0岁(范围2.2至7.6)停用氟氢可的松。
临床怎么用
- 对ASD患儿应尽早启动氟氢可的松治疗以促进追赶生长并控制电解质紊乱。
- 治疗过程中可评估停药可能性,但停药后仍需长期监测类固醇谱与临床状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aldosterone synthase deficiency (ASD) caused by mutations in the CYP11B2 gene is characterized by isolated mineralocorticoid deficiency. Data are scarce regarding clinical and biochemical outcomes of the disease in the follow-up. OBJECTIVE: Assessment of the growth and steroid profiles of patients with ASD at the time of diagnosis and after discontinuation of treatment. DESIGN AND METHOD: Children with clinical diagnosis of ASD were included in a multicenter study. Growth and treatment characteristics were recorded. Plasma adrenal steroids were measured using liquid chromatography-mass spectrometry. Genetic diagnosis was confirmed by CYP11B2 gene sequencing and in silico analyses. RESULTS: Sixteen patients from 12 families were included (8 females; median age at presentation: 3.1 months, range: 0.4 to 8.1). The most common symptom was poor weight gain (56.3%). Median age of onset of fludrocortisone treatment was 3.6 months (range: 0.9 to 8.3). Catch-up growth was achieved at median 2 months (range: 0.5 to 14.5) after treatment. Fludrocortisone could be stopped in 5 patients at a median age of 6.0 years (range: 2.2 to 7.6). Plasma steroid profiles revealed reduced aldosterone synthase activity both at diagnosis and after discontinuation of treatment compared to age-matched controls. We identified 6 novel (p.Y195H, c.1200 + 1G > A, p.F130L, p.E198del, c.1122-18G > A, p.I339_E343del) and 4 previously described CYP11B2 variants. The most common variant (40%) was p.T185I. CONCLUSIONS: Fludrocortisone treatment is associated with a rapid catch-up growth and control of electrolyte imbalances in ASD. Decreased mineralocorticoid requirement over time can be explained by the development of physiological adaptation mechanisms rather than improved aldosterone synthase activity. As complete biochemical remission cannot be achieved, a long-term surveillance of these patients is required.
引用
- Gurpinar Tosun B, Kendir Demirkol Y, Seven Menevse T, et al. Catch-up Growth and Discontinuation of Fludrocortisone Treatment in Aldosterone Synthase Deficiency. J Clin Endocrinol Metab. 2022. PMID: 34415991. doi:10.1210/clinem/dgab619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。